UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 6-K

Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16 under the Securities Exchange Act of 1934

May 15, 2017

Lombard Medical, Inc.
(Exact Name of Registrant as Specified in Its Charter)

Commission File Number 001-36402

N/A
(Translation of Registrant's Name into English)

Cayman Islands	3841	Not applicable
(State or Other Jurisdiction of Incorporation or Organization)	(Primary Standard Industrial Classification Code Number)	(I.R.S. Employer Identification Number)

4 Trident Park
Didcot
Oxfordshire OX11 7HJ
United Kingdom
+44 20 1235 750800
(Address, Including ZIP Code, and Telephone Number, Including Area Code, of Registrant's Principal Executive Offices)

Lombard Medical, Inc.
4 Trident Park
Didcot
Oxfordshire OX11 7HJ
United Kingdom
(Name, Address of Agent for Service)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F:

Form 20-F ☒ Form 40-F ☐

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):___

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):___

Furnished as Exhibit 99.1 to this Report on Form 6-K is a press release of Lombard Medical, Inc. dated May 15, 2017, announcing that it has enrolled and treated the first patient in its global registry to evaluate its Altura® Endograft System.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Lombard Medical, Inc.

Date: May 15, 2017

By: /s/ Kurt Lemvigh
Kurt Lemvigh
Chief Executive Officer

Exhibit 99.1

Lombard Medical Announces First Patient Enrolled and Treated in the ALTITUDE Registry for the Altura® Stent Graft System

OXFORDSHIRE, U.K.--(BUSINESS WIRE)--May 15, 2017--Lombard Medical, Inc. (NASDAQ: EVAR), a developer, manufacturer and marketer of endovascular aortic aneurysm repair products, today announced that it has enrolled and treated the first patient in its global registry to evaluate its Altura® Endograft System.

The **ALTITUDE** registry *(**ALT**ura **I**mpact on the **T**reatment of Abdominal Aortic Aneurysms **U**sing a Novel **D**-stent **E**VAR Design)* is being conducted across a range of UK and international clinical centers to evaluate the use of the Altura Endograft System in 1,000 patients in typical clinical-use conditions.

ALTITUDE's Chief investigator, Paul Hayes, M.D., F.R.C.S., Department of Surgery, University of Cambridge and Addenbrooke's Hospital, Cambridge, UK, commented, "This registry will allow the clinical community of AAA implanters to gain necessary experience with Altura. Given the system's ultra-low profile, its repositionability, the elimination of the contralateral cannulation step and retrograde delivery of the limb sections, this innovative design promises to facilitate a much simpler, faster, more predictable and consistent deployment of the endograft. The launch of this registry confirms Lombard's confidence in the product and will allow us to develop a robust dataset about long-term outcomes."

"I am encouraged by our positive early clinical experience with Altura. The simplicity of planning, accuracy of deployment and repositionability could lead to it becoming a workhorse device in the future. The ALTITUDE registry will provide a real world evaluation of the longer term outcomes," said Simon Kreckler, M.D., F.R.C.S., vascular & endovascular surgeon at Addenbrooke's Hospital, Cambridge, UK.

About Lombard Medical, Inc.

Lombard Medical, Inc. based in Oxfordshire, U.K. develops, manufactures and markets an innovative range of minimally invasive abdominal aortic aneurysm endovascular repair products. For more information, please visit www.lombardmedical.com

Forward-Looking Statements

This announcement contains forward-looking statements that reflect the Company's current expectations regarding future events. These forward-looking statements generally can be identified by the use of words or phrases such as "believe," "expect," "future," "anticipate," "look forward to," "intend," "plan," "foresee," "may," "should," "will," "estimates," "outlook," "potential," "optimistic," "confidence," "continue," "evolve," "expand," "growth" or words and phrases of similar meaning. Statements that describe objectives, plans or goals also are forward-looking statements. Forward-looking statements are subject to risks, management assumptions and uncertainties. Actual results could differ materially from those projected herein and depend on a number of factors, including the success of the Company's research and development and commercialization strategies, the uncertainties related to the regulatory process and the acceptance of the Company's products by hospitals and other medical professionals, the uncertainty of estimated revenues and profits, the uncertainty of current domestic and international economic conditions that could adversely affect the level of demand for the Company's products and increased volatility in foreign exchange rates, the inability to raise additional funds, and the risks, uncertainties and other factors described under the heading "Risk Factors" in the Company's Form 20-F filed with the Securities and Exchange Commission dated May 1, 2017. Readers are urged to consider these factors carefully in evaluating the forward-looking statements. The forward-looking statements included herein are made only as of the date of this report and the Company undertakes no obligation to update these statements in the future.

CONTACT:
Lombard Medical, Inc.
Kurt Lemvigh, +44 (0)1235 750 800
Chief Executive Officer